Press Releases

Announcement from Biovica International’s extra general meeting

The extra general meeting of Biovica International AB (“Biovica” or the “Company”) was held today on 12 October 2021 and the following resolutions were passed by the meeting.

October 12, 2021

Notice of extra general meeting in Biovica International AB

The shareholders of Biovica International AB, reg. no. 556774-6150, (the “Company”) are hereby invited to the extra general meeting on Tuesday 12 October 2021.

September 23, 2021

DiviTum®TKa results from SWOG study published in Clinical Cancer Research

Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.

September 15, 2021

Promising DiviTumTKa results from BioItaLEE study presented at ESMO

Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen the potential of DiviTum®TKa as a treatment monitoring devise for CDK4/6 inhibitor treatments.

September 14, 2021

Biovica provides update on FDA application process

Biovica, active in cancer diagnostics, today announced that the company’s expected timeline for its updated 510(k)-application to the US Food and Drug Administration (FDA) has been prolonged due to delay in response from FDA.

September 13, 2021

Announcement from Biovica International’s annual general meeting

The annual general meeting of Biovica International AB (“Biovica” or the “Company”) was held today on 31 August 2021 and the following resolutions were passed by the meeting.

August 31, 2021

DiviTum®TKa approaching FDA approval

SEK 000s Q1 21/22 Q1 20/21 May-April 20/21 Net sales 381 340 2,077 Operating profit (loss) -12,238 -8,665 -40,181 Profit (loss) for the period -12,225 -8,374 -39,482 Earnings per share, after dilution -0.43 -0.36 -1.39 Significant events during the first quarter The PROMIX breast cancer study at Karolinska University Hospital has been published in the […]

CEO’s presentation ahead of the 2021 Annual General Meeting has been published

Biovica, active in cancer diagnostics, today announced that a pre-recorded presentation with CEO Anders Rylander has been published.

August 27, 2021

Biovica strengthens management team

Biovica, active in cancer diagnostics, today announced that Warren Cresswell has been appointed President Americas and will be part of the management team.

August 10, 2021

Notice of annual general meeting in Biovica International AB

The shareholders of Biovica International AB, reg. no. 556774-6150, (the “Company”) are hereby invited to the annual general meeting on Tuesday 31 August 2021.

July 30, 2021